Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-15

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects 75% of SSc patients and is the leading cause of death in SSc. No diagnostic or prognostic biomarkers of SSc-associated ILD have been validated to date. The search for such a serum biomarker is essential to assess the severity of these patients and to help the therapeutic management.

We have shown that soluble fractalkine is elevated in SSc patients, especially in SSc patients with ILD. The fractalkine is both an endothelial adhesion molecule and a chemokine that binds to the CX3CR1 receptor expressed by immune populations. It would thus reflect the vasculopathy and inflammation that lead to the fibrosing pulmonary involvement of this disease.

Objectives and means: We aim to perform a low-risk interventional biomedical research which main objective is the quantitative evaluation of soluble fractalkine in SSc patients with ILD in comparison with SSc patients without ILD. This epidemiological, explanatory, analytical, single-center study will comprise three groups: 1 / SSc without ILD (control group in the context of SSc), 2/ SSc with ILD and 3/ patients with idiopathic pulmonary fibrosis (IPF) (control group of the ILD). Secondary objectives are evaluation of: 1 / fractalkine levels in the IPF, 2 / correlations between fractalkine levels and severity of ILD and of SSc disease over time, 3 / correlations between fractalkine and 2 other biomarkers: KL-6 (marker of pulmonary fibrosis) and soluble CD146 (sCD146, marker of vasculopathy), 4 / predictive values of the decline in lung function of these 3 markers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis

NCT02636127

Scleroderma, Systemic

COMPLETED NA

Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension

NCT02331225

Systemic Sclerosis Pulmonary Hypertension Scleroderma

COMPLETED

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716

Scleroderma Pulmonary Hypertension

UNKNOWN

Implementation of a Biological Sample Collection in Systemic Sclerosis Patients

NCT04986514

Systemic Sclerosis

NOT_YET_RECRUITING

Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?

NCT05482594

Systemic Sclerosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Scleroderma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SSc without ILD

Group Type EXPERIMENTAL

blood samples

Intervention Type BIOLOGICAL

blood samples

SSc with ILD

Group Type EXPERIMENTAL

blood samples

Intervention Type BIOLOGICAL

blood samples

patients with idiopathic pulmonary fibrosis

Group Type ACTIVE_COMPARATOR

blood samples

Intervention Type BIOLOGICAL

blood samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18 with SSc with or without ILD with a medical follow up in AP-HM
* Patients, followed at AP-HM, with IPF

Exclusion Criteria

* Impossibility of taking blood
* Known diagnosis of respiratory disorders other than SSc-associated ILD and IPF
* An infection in progress
* An evolutive cancer
* Chemotherapy or radiation therapy in progress
* Minors
* Pregnant or lactating women
* Majors under guardianship
* People staying in a health or social facility
* People in emergency
* Non-beneficiaries of a social security scheme
* Persons deprived of their liberty

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No